AESAN’s latest legislative developments include Commission Implementing Regulation (EU) 2024/2694, adopted on October 17, 2024, authorizing the placing on the market of magnesium L-threonate in the European Union as a novel food and amending Implementing Regulation (EU) 2017/2470.
Although magnesium L-threonate is not as widely known as other forms of magnesium, growing research suggests that it may have unique properties. These include improved cognitive function, positive effects on neuronal health related to increased levels of magnesium in the brain, and reduced anxiety.
The Regulation establishes specific conditions on the use of magnesium L-threonate in food products and supplements, including a maximum dose of 250 mg/day. Within the labeling requirements, the importance of adequately informing consumers is emphasized, highlighting that this food supplement “should be consumed only by adults, with the exception of pregnant and lactating women”.
Although there are already studies suggesting specific brain health benefits and high bioavailability, research on magnesium L-threonate continues to develop. This may influence how quickly manufacturers adopt this ingredient into their formulations. While all forms of magnesium can help maintain muscle function, bone health and blood sugar regulation, not all are specifically associated with cognitive benefits. In conclusion, the choice between magnesium L-threonate and other sources of magnesium will depend on specific health goals and individual needs.
Implementing Regulation (EU) 2024/2694 represents an important step in the regulation of novel foods in the European Union and reflects the growing research on the potential benefits of magnesium L-threonate.
